Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
REGULATORY
Japan Launches Panel to Discuss “Social Security for All Generations”
The Japanese government on September 20 launched a new panel to give shape to Prime Minister Shinzo Abe’s campaign to build a “social security system benefiting all generations,” bringing together members of other key councils to sketch out a blueprint…
To read the full story
Related Article
- Final Report from Govt’s All-Generation Social Security Council to Be Delayed until Year-End
May 26, 2020
- Govt’s All-Generation Social Security Panel Compiles Interim Report, No Mention of OTC-Like Drugs
December 23, 2019
- Course of Govt’s “All-Generation” Social Security Reform Could Impact Pharma
December 5, 2019
- “All-Generation” Panel Cites Coverage of OTC-Like Drugs as Policy Issue
November 27, 2019
- MHLW Panel Members Call for Discussion on Range of Health Coverage
September 30, 2019
REGULATORY
- MHLW Updates LDP Project Team on PMD Law Amendment Plans
December 25, 2024
- MHLW Panel Sorts Out Challenges for Stable Supply of Plasma-Derived Products
December 24, 2024
- Deferred PMP Cuts Likely to Batter Stelara; 7 Drugs Subject to Rule after LOE
December 24, 2024
- CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
- Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…